Nomura Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.1M | Sell |
19,562
-20,833
| -52% | -$15.9M | 0.04% | 323 |
|
|
2025
Q4 | $31.2M | Buy |
40,395
+15,663
| +63% | +$10.6M | 0.04% | 229 |
|
|
2025
Q3 | $13.9M | Buy |
24,732
+18,599
| +303% | +$10.5M | 0.02% | 408 |
|
|
2025
Q2 | $3.22M | Sell |
6,133
-3,496
| -36% | -$1.95M | 0.01% | 693 |
|
|
2025
Q1 | $6.11M | Sell |
9,629
-18,172
| -65% | -$12.5M | 0.01% | 640 |
|
|
2024
Q4 | $19.8M | Buy |
27,801
+16,416
| +144% | +$13.8M | 0.03% | 341 |
|
|
2024
Q3 | $12M | Buy |
11,385
+8,218
| +259% | +$9.15M | 0.03% | 389 |
|
|
2024
Q2 | $3.33M | Buy |
3,167
+2,264
| +251% | +$2.19M | 0.01% | 775 |
|
|
2024
Q1 | $869K | Sell |
903
-4,034
| -82% | -$3.84M | ﹤0.01% | 1139 |
|
|
2023
Q4 | $4.34M | Buy |
+4,937
| New | +$4.07M | 0.01% | 713 |
|
|
2023
Q3 | – | Sell |
-1,669
| Closed | -$1.31M | – | 1597 |
|
|
2023
Q2 | $1.2M | Buy |
1,669
+1,095
| +191% | +$844K | ﹤0.01% | 866 |
|
|
2023
Q1 | $472K | Buy |
+574
| New | +$433K | ﹤0.01% | 1141 |
|
|
2022
Q3 | – | Sell |
-584
| Closed | -$347K | – | 1922 |
|
|
2022
Q2 | $347K | Sell |
584
-1,283
| -69% | -$834K | ﹤0.01% | 1196 |
|
|
2022
Q1 | $1.3M | Buy |
1,867
+15
| +0.8% | +$9.49K | ﹤0.01% | 1016 |
|
|
2021
Q4 | $1.17M | Sell |
1,852
-568
| -23% | -$349K | ﹤0.01% | 1161 |
|
|
2021
Q3 | $1.38M | Sell |
2,420
-8
| -0.3% | -$4.97K | ﹤0.01% | 1024 |
|
|
2021
Q2 | $1.36M | Sell |
2,428
-16,972
| -87% | -$8.6M | ﹤0.01% | 994 |
|
|
2021
Q1 | $9.18M | Buy |
19,400
+12,425
| +178% | +$6.05M | 0.02% | 380 |
|
|
2020
Q4 | $3.36M | Buy |
6,975
+4,189
| +150% | +$2.26M | 0.01% | 683 |
|
|
2020
Q3 | $1.56M | Sell |
2,786
-1,355
| -33% | -$822K | ﹤0.01% | 710 |
|
|
2020
Q2 | $2.58M | Buy |
+4,141
| New | +$2.35M | 0.01% | 511 |
|
|
2020
Q1 | – | Sell |
-1,066
| Closed | -$400K | – | 1180 |
|
|
2019
Q4 | $400K | Buy |
+1,066
| New | +$359K | ﹤0.01% | 941 |
|
|
2018
Q3 | – | Sell |
-1,516
| Closed | -$523K | – | 1467 |
|
|
2018
Q2 | $523K | Sell |
1,516
-4,520
| -75% | -$1.41M | ﹤0.01% | 990 |
|
|
2018
Q1 | $2.08K | Sell |
6,036
-1,941
| -24% | -$675K | ﹤0.01% | 835 |
|
|
2017
Q4 | $3M | Buy |
7,977
+1,048
| +15% | +$424K | 0.01% | 761 |
|
|
2017
Q3 | $3.1M | Buy |
6,929
+396
| +6% | +$188K | 0.01% | 711 |
|
|
2017
Q2 | $3.21M | Buy |
+6,533
| New | +$2.86M | 0.01% | 688 |
|
|
2017
Q1 | – | Sell |
-4,730
| Closed | -$1.75M | – | 1566 |
|
|
2016
Q4 | $1.75M | Buy |
+4,730
| New | +$1.8M | ﹤0.01% | 899 |
|
|
2016
Q2 | – | Sell |
-705
| Closed | -$257K | – | 1549 |
|
|
2016
Q1 | $257K | Buy |
705
+32
| +5% | +$13.2K | ﹤0.01% | 1121 |
|
|
2015
Q4 | $365K | Sell |
673
-241
| -26% | -$131K | ﹤0.01% | 1226 |
|
|
2015
Q3 | $413K | Buy |
914
+304
| +50% | +$163K | ﹤0.01% | 1044 |
|
|
2015
Q2 | $301K | Hold |
610
| – | – | ﹤0.01% | 1453 |
|
|
2015
Q1 | $268K | Sell |
610
-5,359
| -90% | -$2.27M | ﹤0.01% | 1391 |
|
|
2014
Q4 | $2.41M | Sell |
5,969
-4,549
| -43% | -$1.79M | 0.01% | 964 |
|
|
2014
Q3 | $3.74M | Sell |
10,518
-4,721
| -31% | -$1.58M | 0.01% | 819 |
|
|
2014
Q2 | $4.37M | Sell |
15,239
-5,597
| -27% | -$1.66M | ﹤0.01% | 739 |
|
|
2014
Q1 | $6.26M | Buy |
20,836
+2,920
| +16% | +$900K | ﹤0.01% | 652 |
|
|
2013
Q4 | $4.95M | Buy |
17,916
+3,880
| +28% | +$1.12M | 0.02% | 401 |
|
|
2013
Q3 | $4.39M | Buy |
14,036
+4,664
| +50% | +$1.23M | 0.03% | 523 |
|
|
2013
Q2 | $2.13M | Buy |
+9,372
| New | +$2.18M | 0.02% | 657 |
|
Other funds holding REGN
VCM
N
Nomura Holdings's REGN Position: Q1 2026 in Review
Nomura Holdings reduced its Regeneron Pharmaceuticals (REGN) stake by 52% in Q1 2026, selling an estimated $15.9M and leaving 19,562 shares worth $15.1M. The position accounts for 0.04% of the portfolio, ranked #323.
Nomura Holdings first reported a position in REGN in Q2 2013 and has held it in 40 quarters since. The position peaked at $31.2M in Q4 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Nomura Holdings held 19,562 shares of Regeneron Pharmaceuticals worth $15.1M as of Q1 2026.
- Nomura Holdings sold 20,833 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15.9M.
- Regeneron Pharmaceuticals made up 0.04% of Nomura Holdings's portfolio in Q1 2026, its #323 holding.
- Nomura Holdings first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- Nomura Holdings's Regeneron Pharmaceuticals position peaked at $31.2M in Q4 2025.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.